Today's Trend
Nkarta, Inc. (NASDAQ: NKTX) is receiving mixed analyst signals. The stock has increased as investors weigh a new “Buy” rating and substantial price-target upside against worsening loss expectations.
- Stifel maintains a bullish view: Stifel Nicolaus lowered its price target from $11 to $10 but initiated or reaffirmed a “Buy” rating. The revised target still implies approximately 329% upside from the referenced $2.33 share price, providing a positive catalyst for Nkarta (NKTX). Ticker Report article
- HC Wainwright cut earnings estimates across the forecast period: The firm reduced its EPS forecasts for the third and fourth quarters of 2026 to losses of $0.46 and $0.48, respectively, and lowered its full-year estimates to losses of $1.86 in 2026, $2.26 in 2027, $1.76 in 2028, $1.53 in 2029 and $1.23 in 2030. These revisions indicate expectations for deeper or more persistent losses, which may pressure NKTX despite HC Wainwright retaining its “Buy” rating and $14 price target. MarketBeat analyst estimates article
Overall, the positive rating and large implied valuation upside are supporting sentiment, but the repeated downward revisions to Nkarta’s projected earnings highlight ongoing financing and execution risks typical of an unprofitable biotechnology company.